Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
| Publicado en: | Lancet Oncology Vol. 27; no. 8; pp. 941 - 959 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Elsevier B.V.
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195654420&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195654420 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14702045 KH2 jtl: Lancet Oncology issn: 14702045 maglogo: N pubinfo: dt: Aug2026 vid: 27 iid: 8 ed: 1077-4114 (Print) pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 195654420 10.1016/S1470-2045(26)00287-1 195654420 ppf: 941 ppct: 18 formats: tig: atl: Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. aug: au: Turner, Nicholas C Mayer, Erica L Park, Yeon Hee Janni, Wolfgang Ma, Cynthia Cristofanilli, Massimo Bianchini, Giampaolo Kalinsky, Kevin Iwata, Hiroji Chia, Stephen Brufsky, Adam M Fasching, Peter A Nowecki, Zbigniew Pascual, Javier Karadurmus, Nuri Gal-Yam, Einav Chung, Wei-Pang Im, Seock-Ah Zambelli, Alberto Dalenc, Florence affil: Royal Marsden Hospital, London, UK sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|